Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T14676
|
||||
| Former ID |
TTDNC00650
|
||||
| Target Name |
APRIL
|
||||
| Gene Name |
TNFSF13
|
||||
| Synonyms |
A proliferation-inducing ligand; CD256; TALL-2; TNF- and APOL-related leukocyte expressed ligand 2; TNF-related death ligand 1; TRDL-1; Tumor necrosis factor ligand superfamily member 13; TNFSF13
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Lymphoma; Graft rejection in heart transplantation; Idiopathic thrombocytopenic purpura [ICD9:202.8, 208.9, 287.31, 996; ICD10: C81-C86, D69.3, T86] | ||||
| Rheumatold arthritis; Multiple sclerosis [ICD9: 340, 710-719, 714; ICD10: G35, M00-M25, M05-M06] | |||||
| Function |
Cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. Plays a role in the regulation of tumor cell growth. May be involved in monocyte/macrophage-mediated immunological processes.
|
||||
| BioChemical Class |
Cytokine: tumor necrosis factor
|
||||
| UniProt ID | |||||
| Sequence |
MPASSPFLLAPKGPPGNMGGPVREPALSVALWLSWGAALGAVACAMALLTQQTELQSLRR
EVSRLQGTGGPSQNGEGYPWQSLPEQSSDALEAWENGERSRKRRAVLTQKQKKQHSVLHL VPINATSKDDSDVTEVMWQPALRRGRGLQAQGYGVRIQDAGVYLLYSQVLFQDVTFTMGQ VVSREGQGRQETLFRCIRSMPSHPDRAYNSCYSAGVFHLHQGDILSVIIPRARAKLNLSP HGTFLGFVKL |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Atacicept | Drug Info | Phase 3 | Lymphoma; Graft rejection in heart transplantation; Idiopathic thrombocytopenic purpura | [1], [2] |
| Atacicept | Drug Info | Phase 2 | Rheumatold arthritis; Multiple sclerosis | [2] | |
| Modulator | Atacicept | Drug Info | [1] | ||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| References | |||||
| REF 1 | Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis. Nervenarzt. 2009 Dec;80(12):1462-72. | ||||
| REF 2 | New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.